Lipohypertrophy is a common skin complication in people with insulin-treated diabetes. Despite its high prevalence and potential impact on diabetes management and outcomes, published data regarding the risk factors for the development of this complication are contradictory. The study aimed to determine risk factors for lipohypertrophy related to patient characteristics and insulin therapy.
Method:
Medical databases (MEDLINE/PubMed, Embase, CENTRAL) were searched from 1990 to August 21, 2023. All relevant studies describing potential risk factors for lipohypertrophy in people with insulin-treated diabetes (eg, sex, age, body mass index [BMI], type of diabetes, and injection technique) were included. Data enabling calculations of prevalence odds ratios (pOR) and mean differences (MD) with 95% confidence intervals [95% CI] were extracted and pooled in meta-analyses.
Results:
Fifty-one studies of risk factors for lipohypertrophy were identified. Performed meta-analyses indicate that the strongest contributor to lipohypertrophy was incorrect injection site rotation (pOR = 8.85 [95% CI: 5.10-15.33]), followed by needle reuse (3.20 [1.99-5.13]), duration of insulin therapy >5 years (2.62 [1.70-4.04]) and >2 daily injections per day (2.27 [1.58-3.25]). Those with type 1 diabetes and obese/overweight individuals also had significantly higher odds of developing lipohypertrophy. Sex, age, and insulin device (pen, syringes) were not significant risk factors for lipohypertrophy.
Conclusions:
This systematic review with meta-analysis revealed that incorrect injection site rotation and needle reuse are the most substantial factors in developing lipohypertrophy. Notably, both factors are modifiable through patient education, emphasizing the importance of teaching proper injection techniques for better diabetes management.
Abu GhazalehHHashemRForbesA, et alA systematic review of ultrasound-detected lipohypertrophy in insulin-exposed people with diabetes. Diabetes Ther. 2018;9(5):1741-1756. doi:10.1007/s13300-018-0472-7.
2.
Al HayekAARobertAABrahamRBAl DawishMA. Frequency of lipohypertrophy and associated risk factors in young patients with type 1 diabetes: a cross-sectional study. Diabetes Ther. 2016;7(2):259-267. doi:10.1007/s13300-016-0161-3.
3.
BlancoMHernándezMTStraussKWAmayaM. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445-453. doi:10.1016/j.diabet.2013.05.006.
4.
BochanenNDecochezKHeleuE, et alLipohypertrophy Monitoring Study (LIMO): effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: confirmation of an unpleasant truth. Diabet Med. 2022;39(1):e14672. doi:10.1111/dme.14672.
5.
The AMD-OSDI Study Group on Injection Techniques and Nefrocenter Research & Nyx Start-up Study Group; GentileSGuarinoGCorteTD, et alInsulin-induced skin lipohypertrophy in type 2 diabetes: a multicenter regional survey in Southern Italy. Diabetes Ther. 2020;11(9):2001-2017. doi:10.1007/s13300-020-00876-0.
6.
GentileSGuarinoGDella CorteT, et alBruising: a neglected, though patient-relevant complication of insulin injections coming to light from a real-life nationwide survey. Diabetes Ther. 2021;12(4):1143-1157. doi:10.1007/s13300-021-01026-w.
7.
GuptaSSGuptaKSGatheSSBamrahPGuptaSS. Clinical implications of lipohypertrophy among people with type 1 diabetes in India. Diabetes Technol Ther. 2018;20(7):483-491. doi:10.1089/dia.2018.0074.
8.
SürücüHAOKur ArslanH. Lipohypertrophy in individuals with type 2 diabetes: prevalence and risk factors. J Caring Sci. 2018;7(2):67-74. doi:10.15171/jcs.2018.011.
9.
ThewjitcharoenYPrasartkaewHTongsumritP, et alPrevalence, risk factors, and clinical characteristics of lipodystrophy in insulin-treated patients with diabetes: an old problem in a new era of modern insulin. Diabetes Metab Syndr Obes. 2020;13:4609-4620. doi:10.2147/DMSO.S282926.
10.
AroraSAgrawalNKShanthaiahDM, et alEarly detection of cutaneous complications of insulin therapy in type 1 and type 2 diabetes mellitus. Prim Care Diabetes. 2021;15(5):859-864. doi:10.1016/j.pcd.2021.06.004.
11.
BarolaATiwariPBhansaliA, et alInsulin-related lipohypertrophy: lipogenic action or tissue trauma?Front Endocrinol. 2018;9:1-8. doi:10.3389/fendo.2018.00638.
12.
GentileSStrolloFSattaE, et alInsulin-related lipohypertrophy in hemodialyzed diabetic people: a multicenter observational study and a methodological approach. Diabetes Ther. 2019;10(4):1423-1433. doi:10.1007/s13300-019-0650-2.
13.
HajheydariZKashiZAkhaOAkbarzadehS. Frequency of lipodystrophy induced by recombinant human insulin. Eur Rev Med Pharmacol Sci. 2011;15(10):1196-1201.
14.
KumarRGuptaRDShettyS, et alLipohypertrophy in insulin injecting patients with diabetes mellitus: an under-recognized barrier for glycemic control. Int J Diabetes Dev Ctries. 2021;41(2):329-336. doi:10.1007/s13410-020-00889-2.
15.
WangKZhangSLiuCChenY. A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy. Therapie. 2021;76(6):617-628. doi:10.1016/j.therap.2021.04.002.
16.
Al AjlouniMAbujbaraMBatiehaAAjlouniK. Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2015;13(2):e20776. doi:10.5812/ijem.20776.
17.
HaunerHStockampBHaastertB. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104(2):106-110. doi:10.1055/s-0029-1211431.
18.
KiracCGonulluCBaldaneS, et alEffect of vitamin D deficiency on the frequency of lipohypertrophy occurrence in patients with type 2 diabetes mellitus under injectable treatment. Turk J Endocrinol Metab. 2020;24:184-188. doi:10.25179/tjem.2020-74469.
19.
NawazAHashamMAShireenM, et alPrevalence of lipohypertrophy and its associations in insulin-treated diabetic patients. Pak J Med Sci. 2022;39(1):209-213. doi:10.12669/pjms.39.1.6134.
20.
ElsayedSSolimanATDe SanctisV, et alInsulin-induced lipodystrophy and predisposing factors in children and adolescents with type 1 diabetes mellitus (T1DM) in a tertiary care Egyptian center. Acta Biomed. 2023;94(3):e2023078. doi:10.23750/abm.v94i3.14117.
21.
BaruahMPKalraSBoseSDekaJ. An audit of insulin usage and insulin injection practices in a large Indian cohort. Indian J Endocrinol Metab. 2017;21(3):443-452. doi:10.4103/ijem.IJEM_548_16.
22.
GentileSGuarinoGDella CorteT, et alThe economic burden of insulin injection-induced lipohypertrophy. role of education: the ISTERP-3 study. Adv Ther. 2022;39(5):2192-2207. doi:10.1007/s12325-022-02105-5.
23.
JiLSunZLiQ, et alLipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact. Diabetes Technol Ther. 2017;19(1):61-67. doi:10.1089/dia.2016.0334.
24.
VardarBKizilciS. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77(2):231-236. doi:10.1016/j.diabres.2006.12.023.
25.
GentileSGuarinoGDella CorteT, et alWhy do so many people with type 2 diabetes who take insulin have lipohypertrophy? Fate or educational deficiencies?Diabetes Ther. 2023;14(1):179-191. doi:10.1007/s13300-022-01341-w.
26.
LinYLinLWangWHongJZengH. Insulin-related lipohypertrophy: ultrasound characteristics, risk factors, and impact of glucose fluctuations. Endocrine. 2022;75(3):768-775. doi:10.1007/s12020-021-02904-w.
27.
HawaATengCLDevarajNK, et alPrevalence and associated factors of lipohypertrophy in insulin-injected patients with diabetes in selected primary care clinics in Peninsular Malaysian: a cross-sectional study. Malays Fam Physician. 2023;18:37. doi:10.51866/oa.100.
28.
PahujaVPunjotPFernandesG, et alExploring the factors associated with lipohypertrophy in insulin-treated type 2 diabetes patients in a tertiary care hospital in Mumbai, India. Int J Diabetes Dev Ctries. 2019;39(3):426-431. doi:10.1007/s13410-019-00735-0.
29.
CunninghamMTMcKennaM. Lipohypertrophy in insulin-treated diabetes: prevalence and associated risk factors. J Diabetes Nurs. 2013;17(9):340-343.
30.
PozzuoliGMLaudatoMBaroneMCrisciFPozzuoliB. Errors in insulin treatment management and risk of lipohypertrophy. Acta Diabetol. 2018;55(1):67-73. doi:10.1007/s00592-017-1066-y.
31.
KorkmazFNGökçay CanpolatAGüllüS. Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes. Endocrinología, Diabetes Y Nutrición. 2022;69(5):354-361. doi:10.1016/j.endinu.2021.07.002.
32.
ShettyZPsLKulkarniS, et alScreening of Lipohypertrophy (LH) in type 1 and type 2 diabetes patients and factors influencing this condition. EMIJ. 2018;6(5):309-312. doi:10.15406/emij.2018.06.00203.
33.
StrolloFGuarinoGArmentanoV. Unexplained hypoglycaemia and large glycaemic variability: skin lipohypertrophy as a predictive sign. Diabetes Res. 2016;2(1):24-32.
34.
WyshamCHRosenstockJVetterMLWangHHardyEIqbalN. Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. BMJ Open Diabetes Res Care. 2020;8(1):e000773. doi:10.1136/bmjdrc-2019-000773.
35.
GentileSStrolloF. Subcutaneous nodules during treatment with an exenatide long-actin once-weekly formulation: an ultrasound evaluation. Diver Equal Health Care. 2016;13(4):313-318.
36.
PageMJMcKenzieJEBossuytPM, et alThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
37.
MoolaSMunnZTufanaruC, et alChapter 7: systematic reviews of etiology and risk. In: Joanna Briggs Institute Reviewer’s Manual. Adelaide, South Australia: The Joanna Briggs Institute; 2017.
38.
TufanaruCMunnZAromatarisE, et alChapter 3: systematic reviews of etiology and risk. In: Joanna Briggs Institute Reviewer’s Manual. Adelaide, South Australia: The Joanna Briggs Institute; 2017.
39.
WallaceBLajeunesseMDietzG, et alOpenMEE: intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol. 2017;8:941-947. doi:10.1111/2041-210X.12708.
40.
AbujbaraMKhreisatEAKhaderYAjlouniKM. Effect of insulin injection techniques on glycemic control among patients with diabetes. Int J Gen Med. 2022;15:8593-8602. doi:10.2147/IJGM.S393597.
41.
AlJaberANSalesIAlmigbalTHWajidSBataisMA. The prevalence of lipohypertrophy and its associated factors among Saudi patients with type 2 diabetes mellitus. J Taibah Univ Med Sci. 2020;15(3):224-231. doi:10.1016/j.jtumed.2020.03.006.
42.
BarlasTYalcinMMCoskunM, et alEvaluation of lipohypertrophy in patients with type 1 diabetes mellitus on multiple daily insulin injections or continuous subcutaneous insulin infusion. Endocr Pract. 2023;29(2):119-126. doi:10.1016/j.eprac.2022.11.008.
43.
De ConinckCFridAGasparR, et alResults and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2(3):168-179. doi:10.1111/j.1753-0407.2010.00077.x.
44.
DeebAAbdelrahmanLTomyM, et alImpact of insulin injection and infusion routines on lipohypertrophy and glycemic control in children and adults with diabetes. Diabetes Ther. 2019;10(1):259-267. doi:10.1007/s13300-018-0561-7.
45.
FridAHHirschLJMenchiorARMorelDRStraussKW. Worldwide injection technique questionnaire study: injecting complications and the role of the professional. Mayo Clin Proc. 2016;91(9):1224-1230. doi:10.1016/j.mayocp.2016.06.012.
46.
GunhanHGElbasanOImreEYavuzDG. Lipodystrophy frequency according to insulin treatment regimen in type 2 diabetic patients: is insulin injection frequency matters in analog insulin era. Acta Endocrinol (Buchar). 2022;18(2):202-208. doi:10.4183/aeb.2022.202.
47.
KakourouTDacou-VoutetakisCKavadiasGBakoulaCAroniK. Limited joint mobility and lipodystrophy in children and adolescents with insulin-dependent diabetes mellitus. Pediatr Dermatol. 1994;11(4):310-314. doi:10.1111/j.1525-1470.1994.tb00094.x.
48.
KlimontovWLazarevMMakhotinA, et alInsulin-induced lipohypertrophy: clinical and ultrasound characteristics. Diabetes Mellitus. 2018;21(4):255-263. doi:10.14341/DM9549.
49.
LiFFFuSMLiuZP, et alInjection sites lipohypertrophy among 736 patients with type 2 diabetes of different-grade hospitals. Int J Clin Exp Med. 2016;9(7):13178-13183.
50.
LuoDShiYZhuM, et alSubclinical lipohypertrophy—easily ignored complications of insulin therapy. J Diabetes Complications. 2021;35(3):107806. doi:10.1016/j.jdiacomp.2020.107806.
51.
NainRAThomasDC. Lipohypertrophy prevalence and its associated risk factors in insulin-treated patients with type 2 diabetes in North Borneo, Malaysia. Belitung Nurs J. 2022;8(6):521-528. doi:10.33546/bnj.2246.
52.
OmarMAEl-KafouryAAEl-ArabyRI. Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors. BMC Res Notes. 2011;4(1):290. doi:10.1186/1756-0500-4-290.
53.
SaeedMAslamWAhmadM, et alFrequency and risk factors of lipohypertrophy in insulin treated patients with diabetes: an experience from a tertiary care center in Multan. Med Forum Monthly. 2022;33(8):78-82.
54.
Saez de IbarraLGallegoF. Factors related to lipohypertrophy in insulin-treated diabetic patients: role of educational intervention. Pract Diab Int. 1998;15(1):9-11.
55.
SawatkarGUKanwarAJDograSBhadadaSKDayalD. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 South Asian patients. Br J Dermatol. 2014;171(6):1402-1406. doi:10.1111/bjd.13077.
56.
SharmaMKumarRRohillaLAngrupAYadavJDayalD. Effect of reuse of insulin needle on glycaemic control and related complications in children with type 1 diabetes mellitus: a prospective observational study. Indian J Endocrinol Metab. 2022;26(2):167-172. doi:10.4103/ijem.ijem_407_21.
57.
SinghaABhattacharjeeRDalalBS, et alAssociations of insulin-induced lipodystrophy in children, adolescents, and young adults with type 1 diabetes mellitus using recombinant human insulin: a cross-sectional study. J Pediatr Endocrinol Metab. 2021;34(4):503-508. doi:10.1515/jpem-2020-0556.
58.
TsadikAGAteyTMNediTFantahunBFeyissaM. Effect of insulin-induced lipodystrophy on glycemic control among children and adolescents with diabetes in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. J Diabetes Res. 2018;2018:4910962-4910967. doi:10.1155/2018/4910962.
59.
MunsterHEvan SandeCPvan de VoorhoevePG, et alDermatological complications of insulin therapy in children with type 1 diabetes. Eur Diabetes Nurs. 2014;11(3):79-84. doi:10.1002/edn.255.
60.
ZureikAJullaJBErginayA, et alPrevalence, severity stages, and risk factors of diabetic retinopathy in 1464 adult patients with type 1 diabetes. Graefes Arch Clin Exp Ophthalmol. 2021;259(12):3613-3623. doi:10.1007/s00417-021-05298-7.
61.
DengNZhangXZhaoF, et alPrevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. J Diabetes Investig. 2018;9(3):536-543. doi:10.1111/jdi.12742.
62.
GrassiGScunteroPTrepiccioniRMarubbiFStraussK. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Transl Endocrinol. 2014;1(4):145-150. doi:10.1016/j.jcte.2014.07.006.
63.
AMD-OSDI Study Group on Injection Technique, Nefrocenter Research and Nyx Start-Up; GentileSGuarinoGDella CorteT, et alRole of structured education in reducing lypodistrophy and its metabolic complications in insulin-treated people with type 2 diabetes: a randomized multicenter case–control study. Diabetes Ther. 2021;12(5):1379-1398. doi:10.1007/s13300-021-01006-0.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
